Section Review: Oncologic, Endocrine & Metabolic: Liposomal chemotherapy for AIDS-related Kaposi's sarcoma

References

• BERAL V: The epidemiology of cancer in AIDS patients. AIDS (1991) 5\(Suppl. 2):99–103.
   Google Scholar
• MILES SA, WANG H, ELASHOFF R, MITSUYASU RT: Im-proved survival for patients with AIDS-related Kaposi's sarcoma. J. Clin. Oncol. (1994) 12(9):1910–1916.
   PubMed Web of Science ®Google Scholar
• MOORE PS, CHANG Y: Detection of herpesvirus -like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. New Engl. J. Med. (1995) 332(18):1181–1185.
   PubMed Web of Science ®Google Scholar
• CHANG Y, CESARMAN E, PESSIN MS, LEE F, CULPEPPER J,KNOWLES DM, MOORE PS: Identification of herpesvirus-like DNA sequences in AIDS associated Kaposi's sar-coma. Science (1994) 266(5192):1865–1869.
   PubMed Web of Science ®Google Scholar
• SU IJ, HSU YS, CHANG YC, WANG IW: Herpesvirus likeDNA sequence in Kaposi's sarcoma from AIDS and non AIDS patients In Taiwan. Lancet (1995) 345(8951):722–723.
   PubMed Web of Science ®Google Scholar
• COHEN J: Controversy: Is KS really caused by new herpesvirus? Science (1995) 268: 1847-1848.
   Google Scholar
• KROWN SE, METROKA C, WERNZ JC, FOR THE AIDS CLINICAL TRIALS GROUP ONCOLOGY COMITTEE:Kaposi's sarcoma in the acquired immune defidency syndrome: a proposal for uniform evaluation, response and staging criteria. AIDS Clinical Trials Group Oncol-ogy Committee. J. Clin. OncoL (1989) 7(9):1201–1207.
   PubMed Web of Science ®Google Scholar
• This manuscript defines stage, and response criteria for the treatment of AIDS-related KS and is used as a reference basis for future studies of treatment of KS.
   Google Scholar
• GOMPELS MM, HILL A, JENKINS P, PETERS B, TOMLINSON D, HARRIS JR, STEWART S, PINCHING AJ, MUNRO AJ: Kaposi's sarcoma in HIV infection treated with bleomy-cin and vincristine. AIDS (1992) 6(10):1175–1180.
   PubMed Web of Science ®Google Scholar
• GILL PS, MILES SA, MITSUYASU RT, MONTGOMERY T,MCCARTHY S, ESPINA BM, FELDSTEIN M, LEVINE AM: Phase I AIDS Clinical Trials Group (075) study of adriamycin, bleomycin and vincristine chemotherapy with zidovudine in the treatment of AIDS-related Kaposi's sarcoma. AIDS (1994) 8(12):1695–1699.
   PubMed Web of Science ®Google Scholar
• SAVILLE MW, LIETZAU J, PLUDA JM, FEUERSTEIN I, ODOMJ, WILSON WH, HUMPHREY RW, FEIGAL E, STEINBERG SM, BRODER S: Treatment of HIV-assodated Kaposi's sar-coma with paclitaxeL Lancet (1995) 346:26–29.
   Google Scholar
• BAILEY J, PLUDA JM, FOLI A, SAVILLE MW, BAUZA 5,ADAMSON PC, MURPHY RE, COHEN RB, BRODER S, DONE-HOWER RC: Phase I/II study of intermittent all trans retinoic add, alone and in combination with interferon alfa 2a, in patients with epidemic Kaposi's sarcoma.]. Clin. Oncol. (1995) 13(8):1966–1974.
   Google Scholar
• HARRIS PJ: Treatment of Kaposi's sarcoma and othermanifestations of AIDS with human chorionic gonado-trophin. Lancet (1995) 346:118–119.
   PubMed Web of Science ®Google Scholar
• NORTHFELT DW, ROBLES R, LANG W, WAGNER B, KAHNJ, BONNEM E: Phase I/II study of intravenous platelet factor 4 (rPF4) in AIDS-related Kaposi's sarcoma. Proc. ASCO (1995) 14:Abstract 820.
   Google Scholar
• GABIZON AA: Selective tumour localization and un-proved therapeutic index of anthracyclines encapsulated in long circulating liposomes. Cancer Res. (1992) 52:891–896.
   PubMed Web of Science ®Google Scholar
• KLIBANOV AL, MARUYAMA K, TORCHILIN VP, HUANG L.Amphipathic polyethyleneglycols effectively prolong the circulation times of liposomes. FESS Lett. (1990) 268:235–237.
   Google Scholar
• HUANG SK, MAYHEW E, GILIANI S, LASIC DD, MARTIN FJ,PAPAHADOPOULOS D: Pharmacokinetics and therapeu-tics of sterically stabilised liposomes in mice bearing C 26 colon cardnoma. Cancer Res. (1992) 52:6774–6781.
   PubMed Web of Science ®Google Scholar
• HUANG SK, MARTIN FJ, JAY G, VOGEL J, PAPAHADJOPOU- LOS D, FRIEND DS: Extravasation and transcytosis ofliposomes in Kaposi's sarcoma like dermal lesions of transgenic mice bearing the HIV tat gene. Am. J. Pathol. (1993) 143:10–14.
   PubMed Web of Science ®Google Scholar
• Demonstrated mode of action of liposomes with a KS-like lesion.
   Google Scholar
• MASOOD R, HUSAIN SR, RAHMAN A, GILL P: Potentiation of cytotoxicity of Kaposi's sarcoma related to immu-nodeficiency syndrome by liposome encapsulated dox-orubkin. AIDS Res. Hum. Retroviruses (1993) 8(9):741–746.
   Google Scholar
• FORSSEN EA, COULTER DM, PROF1TT RT: Selective in vivolocalization of daunorubicin small unilamellar vesicles In solid tumours. Cancer Res. (1992) 52:3255–3261.
   PubMed Web of Science ®Google Scholar
• FORSSEN EA, ROSS ME: DaunoXome treatment of solidtumours: Preclinical and clinical investigations. J. Liposome Research (1994) 4(1):481–512.
   Google Scholar
• GILL PS, ESPINA BM, MUGGIA F, CABRIALES S, TULPLTLE A, ESPLIN JA, LIEBMAN HA, FORSSEN EA, ROSS ME, LEVINEAM: Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J. Clin. Oncol. (1995) 13(4):996–1003.
   PubMed Web of Science ®Google Scholar
• This paper demonstrates that DaunoXome has an improved phar-macokinetic profile when compared with the free drug, has signifi-cant antitumour activity and is well tolerated.
   Google Scholar
• PRESANT CA, SCOLARO M, KENNEDY P, BLAYNEY DW,FLANAGAN B, LISAK J, PRESANT J: Liposomal daunoru-bidn treatment of HIV associated Kaposi's sarcoma. Lancet (1993) 341:1242–1243.
   PubMed Web of Science ®Google Scholar
• MONEY KYRIE JF, BATES F, READY J, GAZZARD BG,PHILLIPS RH, BOAG FC: Liposomal daunorubicin in advanced Kaposi's sarcoma: a Phase 2 study. Clin. Oncol. (R. Coll. Radiol.) (1993) 5:367–371.
   PubMedGoogle Scholar
• SCHURMANN D, DORMANN A, GRUNEWALD T, RUF B: Successful treatment of AIDS-related pulmonary Kaposi's sarcoma with liposomal daunorubicin. Eur. Respir. J. (1994) 7:824–825.
   PubMed Web of Science ®Google Scholar
• BAKKER PJ, DANNER SA, TEN NAPPEL CH, /CROON FP,SPRENGER HG, VAN LEUSEN R, MEENHORST PL, MUUSERS A, VEENHOF CH: Treatment of poor prognosis epidemic Kaposi's sarcoma with doxorubicin, bleomycin, yin-desine and recombinant human granulocyte-monocyte colony stimulating factor (rh GM-GCSF). Eur. J. Cancer (1995) 31A(2):188–192.
   PubMed Web of Science ®Google Scholar
• GILL PS, WERNZ J, SCADDEN DT, COHEN P, VON ROEN J,CHEW T, KEMPIN S, SILVERBERG I, GONZALES G, MYER A, SHEPHERD F, SAWA C, MUKWAYA G, PIKE M, ROSS M: A randomised trial of liposomal daunorubicin (DaunoXome) versus adriamycin, bleomycin and vin-cristine (Ally) in 232 patients with advanced AIDS-re-lated Kaposi's sarcoma. Proc. ASCO (1995) 14:Abstract 830.
   Google Scholar
• HUANG SK, LEE KD, HONG K, FRIEND DS, PAPAHAD-JOPOULOS D: Microscopic localisation of sterically staWised liposomes in colon carcinoma bearing mice. Cancer Res. (1992) 52:5135–5143.
   PubMed Web of Science ®Google Scholar
• YUAN F, LEUNIG M, HUANG SK, BERK DA, PAPAHAD- JOPOULOS D, JAIN RK: Microvascular permeability and Interstitial penetration of sterically stabilised (Stealth) liposomes in a human tumour xenograft. Cancer Res. (1994) 54:3352–3356.
   PubMed Web of Science ®Google Scholar
• Elegant demonstration of stable deposition of extravasated liposomes within tumour xenografts.
   Google Scholar
• VAAGE J, MAYHEW E, LASIC D, MARTIN F: The therapy of primary and metastatic mouse mammary carcinoma with doxorubicin encapsulated in long circulating liposomes. Int. J. Cancer (1992) 51:942–948.
   PubMed Web of Science ®Google Scholar
• VAAGE J, DONOVAN D, MAYHEW E, ULSTER P, WOODLE M: Therapy of mouse mammary carcinomas with vitt-cristine and doxorubicin encapsulated in sterically sta- bilised liposomes. Intl. Cancer(1993) 54:959–964.
   PubMed Web of Science ®Google Scholar
• NORTHFELT DW, MARTIN FJ, KAPLAN LD, RUSSELL J, ANDERSON M. LANG J, VOLBERDING PA: Pharmacokinet-ks, tumour localization and safety of Doxil (liposomal doxorubicin) in AIDS patients with Kaposi's sarcoma. Proc. ASCO (1993) 12:Abstract 8.
   Google Scholar
• NORTHFELT DW: Stealth liposomal doxorubicin delivers more doxorubicin to AIDS KS lesions than to normal skin. Proc. ASCO (1994) 13:Abstract 5.
   Google Scholar
• GABIZON A, CATANE R, UZIELY B, KAUFMAN B, SAFRA T, MARTIN F, HUANG A, BARENHOLZ Y: Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene glycol coated liposomes. Cancer Res. (1994) 54:987-992. Phartnacokinetics of doxorubicin altered by Dox-SL and follow a pattern demonstrated by the liposome carrier.
   Google Scholar
• BOGNER JR, KRONAWITTER U, ROLINSKI B, TRUEBENACH K, GOEBEL FD: Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi's sarcoma. J. AIDS (1994) 7(5):463–468.
   PubMed Web of Science ®Google Scholar
• Clinical effectiveness of Dox-SL.
   Google Scholar
• HENGGE UR, BROCKMEYER NH, BAUMANN M, REIMANN G, GOOS M: Liposomal doxorubicin in AIDS-related Kaposi's sarcoma. Lancet (1993) 342(8869):497.
   PubMed Web of Science ®Google Scholar
• SIMPSON JK, MILLER RF, SPITTLE ME: Liposomal doxoru-hick' for the treatment of AIDS-related Kaposi's sar-coma. Clin. Oncol. (R. Coll. Radiol.) 5(6):372–374.
   Google Scholar
• HARRISON M, TOMLINSON D, STEW/ART S: Liposomal seentrapped doxorubicin: an active agent in AIDS-relatedKaposi's sarcoma. J. Clin. Oncol. (1995) 13(4):914–920. Clinical effectiveness of Dox-SL in a single centre.
   Google Scholar
• GORDON KB, TAJUDDIN A, GUITART J, KUZEL TM, ERAMO LR, VON ROENN J: Hand foot syndrome associated with liposome encapsulated doxorubicin therapy. Cancer (1995) 75(8):2169–2173.
   PubMed Web of Science ®Google Scholar
• ECKARDT JR, CAMPBELL E, BURRIS HA, WEISS GR, RO-DRIGUEZ GI, FIELDS SM, THURMAN AM, PEACOCK NW, COBB P, ROTHENBERG ML, ET AL: A Phase II trial of DaunoXome, liposome encapsulated daunorubicitt, in patients with metastatic adenocarcinoma of the colon. Am. J. Clin. Oncol. (1994) 17(6):498–501.
   PubMedGoogle Scholar
• GUAGLIANONE P, CHAN K, HANISCH R, JEFFERS S, MUG-GIA F, KEMPF R, FORSSEN E: Phase I clinical trial of liposomal daunorubicin (DaunoXome) in advanced malignancies. Proc. ASCO (1992) 11:Abstract 361.
   Google Scholar
• UZIELY B, JEFFERS S, ISACSON R, KUTSCH K, WEI-TSAO D, YEHOSHUA Z, LIBSON E, MUGGIA FM, GABIZON A: Liposomal doxorubicin: antiturnour activity and unique toxicities during two complementary Phase I studies. J. Clin. Oncol. (1995) 13(7):1777–1785.
   PubMed Web of Science ®Google Scholar
• LAUKKANEN ML, ALFTHAN L, KEINANEN K: Functional immtmoliposomes harbouring a biosynthetically lipid tagged single chain antibody. Biochem. (1994) 33:11664–11670.
   PubMed Web of Science ®Google Scholar
• SUZUKI S, UNO S, FUKUDA Y, AOKI Y, MASULO T, HASHIMOTO Y: Cytotoxicity of anti c erbB2 inununo-liposomes containing doxorubicin on human tumour cells. Br.J. Cancer (1995) 72:663–668.
   PubMed Web of Science ®Google Scholar
• AHMAD I, LONGENECKER M, SAMUEL J, ALLEN TM: Anti-body targeted delivery of doxorubicin entrapped in sterically stabilised liposomes can eradicate lung carci-nomas in mice. Cancer Res. (1993) 53:1484–1488.
   PubMed Web of Science ®Google Scholar
• PINNADUWAGE P, HUANG L: Stable target sensitive im-munoliposomes. Blochem. (1992) 31:2850–2855.
   Google Scholar
• GONDAL JA, PREUSS HG, SCHWARTZ R, RAHMAN A: Comparative pharmacological, toxicological and anti tumoral evaluation of free and liposome encapsulated cisplatin in rodents. Eur.J. Cancer (1993) 29A:1536–1542.
   PubMed Web of Science ®Google Scholar
• PEREZ SOLER R, ZOU Y, STEPHENS SL, REDDY S, PRIEBE W: Preclinical toxicity of the lipophilic and non cross resistant anthracycline Annamycin incorporated in liposomes. Proc. Am. Assoc. Clin. Res. (1995) 36:Abstract 2183.
   Google Scholar
• NING S, MACLOED K, ABRA RM, HUANG AH, HAHN GM:Hyperthermia induces doxorubicin release from long circulating liposomes and enhances their anti tumour activity. Int. J. Radiat. Oncol. Biol. Phys. (1994) 29(4):827–834.
   PubMed Web of Science ®Google Scholar